Annovis Bio: Positive Phase 2 Alzheimer's Cognition Data Strengthens Bullish ThesisSeeking Alpha • 05/23/21
Annovis Bio's Stock Trading Higher As Alzheimer's/Parkinson's Candidate Shows Cognitive ImprovementBenzinga • 05/21/21
Annovis Bio Announces Positive Phase 2 Data - ANVS401 Improves Cognition in Alzheimer's Disease - Patients' Cognition Improved 3.3 Points on ADAS-Cog11Newsfile Corp • 05/21/21
Annovis Bio to Participate in Alzheimer Disease Panel Presented by Maxim Group LLC and Hosted by M-Vest on May 26th, 2021Newsfile Corp • 05/20/21
Annovis Bio Announces Positive Phase 2 Data: ANVS401 Significantly Lowers Inflammatory Markers in Parkinson's PatientsNewsfile Corp • 05/19/21
Annovis Bio Appoints Accomplished Neuroscientist, Dr. Cheng Fang as VP of ResearchNewsfile Corp • 05/18/21
Annovis Bio Files for FDA Orphan Drug Designation for ANVS401 for the Treatment of Alzheimer's Disease in Persons with Down SyndromeNewsfile Corp • 05/13/21
Annovis Bio Receives US Patent for Method of Treating Frontotemporal Dementia and Chronic Traumatic EncephalopathyNewsfile Corp • 05/06/21
Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down SyndromeNewsfile Corp • 04/29/21
Annovis Bio Appoints Reid McCarthy to Board and to Role of Audit Committee ChairmanNewsfile Corp • 04/15/21
Annovis Bio Presenting at M Vest and Maxim Group Inaugural Emerging Growth Virtual ConferenceNewsfile Corp • 03/17/21
Annovis Bio Stock Is Trading Higher After Parkinson's Med Shows Improvement In Speed, CoordinationBenzinga • 03/16/21
Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's PatientsNewsfile Corp • 03/16/21